Mauget-Faÿsse M. · Sukkarieh G. · Jebrane H. · Lafolie J. · Alonso A.S. · Laumonier E. · Derrien S. · Le Guern V. · Behar-Cohen F. · Thevenin S. · Augé E. · Guillaume J. · Vasseur V. · Costedoat-Chalumean N.

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details Abstract

Abstract : Introduction: The performance of “en-face” optical coherence tomography (OCT) in screening for chloroquine (CQ) or hydroxychloroquine (HCQ) retinopathy has not been largely explored. The aim of this study was to determine the concordance of “en-face” OCT with multifocal electroretinography (mfERG) in screening for CQ/HCQ retinopathy. Methods: This is a prospective cohort study conducted at the Rothschild Foundation Hospital – Paris between August 2016 and February 2021. Patients taking hydroxychloroquine were followed up over 2 consecutive years and received an “en-face” OCT and a mfERG on each visit. Results: A total of 91 patients (182 eyes) were analyzed. mfERG and “en-face” OCT were concordant in 147 eyes (86.3%). Cohen’s Kappa coefficient for concordance between mfERG and “en-face” OCT was considered weak with a value 0.61 (95% CI: 0.50-0.72). The sensitivity and specificity of “en-face” OCT are 70% (95% CI: 59-79%) and 91% (95% CI: 83-96%) respectively, relatively to mfERG. Proportion of abnormal R2/R5 and R3/R5 ratios did not differ between patients with normal and abnormal “en-face” OCT (p=0.2). Discussion/Conclusion: “En-face” OCT and mfERG have low concordance and cannot be used interchangeably as each investigation evaluates a different facet of CQ/HCQ retinopathy. “En-face” OCT could be used as a complement in screening for CQ/HCQ retinal toxicity if the anomalies detected on “en-face” OCT are confirmed by B-scan OCT sections.

S. Karger AG, Basel

Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.